Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of Salmonella enterica serovar Typhimurium strains with mutations in three SPI-2 co-expressed tested for their ability to cause disease in mice
Salmonella must express and deploy a type III secretion system located in Salmonella pathogenicity island 2 (SPI-2) in order to survive in host phagocytic vacuoles and to cause systemic infection in mouse models of typhoid fever. A genome-wide approach to screening for Salmonella genes that are tran...
ORGANISM(S): Salmonella enterica serovar Typhimurium 
2005-10-07 | E-SMDB-1981 | biostudies-arrayexpress
TranscriptomicsSwitch from LB pH7 to M9 pH5
Salmonella must express and deploy a type III secretion system located in Salmonella pathogenicity island 2 (SPI-2) in order to survive in host phagocytic vacuoles and to cause systemic infection in mouse models of typhoid fever. A genome-wide approach to screening for Salmonella genes that are tran...
ORGANISM(S): Salmonella enterica subsp. enterica serovar Typhimurium 
2005-12-02 | E-GEOD-3735 | biostudies-arrayexpress
UnknownCaspase-8 promotes c-Rel-dependent inflammatory cytokine expression and resistance against <i>Toxoplasma gondii</i>.
Not available
S-EPMC6575527 | biostudies-literature
UnknownInflammatory monocytes promote granuloma control of Yersinia infection.
Not available
S-EPMC10653359 | biostudies-literature
UnknownA Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Not available
S-EPMC8518716 | biostudies-literature
UnknownMeasuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Not available
S-EPMC4188544 | biostudies-literature
UnknownHigher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10156147 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
UnknownTime-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Not available
S-EPMC12214479 | biostudies-literature
UnknownExploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Not available
S-EPMC12170883 | biostudies-literature
Sort   by:  
 Page size